OTCMKTS:NRIFF Nuvo Pharmaceuticals (NRIFF) Stock Price, News & Analysis → WARNING about the death of the U.S. dollar… (From Colonial Metals) (Ad) Free NRIFF Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range$0.75▼$0.7552-Week Range N/AVolume3,000 shsAverage Volume7,337 shsMarket Capitalization$8.52 millionP/E Ratio18.69Dividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Nuvo Pharmaceuticals alerts: Email Address Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Nuvo PharmaceuticalsNuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. Nuvo Pharmaceuticals was founded on August 22, 1983 and is headquartered in Mississauga, Canada.Read More Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. NRIFF Stock News HeadlinesFebruary 14, 2024 | forbes.com4 Best Home Oxygen Concentrators Of 2024July 29, 2021 | benzinga.comMiravo HealthcareTM Ireland Enters into Suvexx® License and Supply Agreement with SK Chemicals Co., Ltd. for South KoreaSee More Headlines Receive NRIFF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:NRIFF CUSIPN/A CIKN/A Webwww.nuvopharmaceuticals.com Phone(905) 673-6980FaxN/AEmployees99Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.04 Trailing P/E Ratio18.69 Forward P/E RatioN/A P/E GrowthN/ANet Income$2.53 million Net Margins-2.81% Pretax MarginN/A Return on Equity8.02% Return on Assets1.11% Debt Debt-to-Equity Ratio5.27 Current Ratio2.67 Quick Ratio2.11 Sales & Book Value Annual Sales$52.41 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow0.82 Book Value$1.59 per share Price / BookN/AMiscellaneous Outstanding Shares11,400,000Free FloatN/AMarket Cap$8.52 million OptionableNot Optionable Beta1.57 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesJesse LedgerPresident & Chief Executive OfficerKelly DemerinoChief Financial OfficerBernard ChiassonChief Scientific OfficerWade HullVice President-Research & DevelopmentKatina K. LoucaidesSecretary, Vice President & General CounselKey CompetitorsGraybug VisionNASDAQ:GRAYCan-Fite BioPharmaNYSE:CANFAvenir Wellness SolutionsOTCMKTS:CURRVaccinexNASDAQ:VCNXMedicureOTCMKTS:MCUJFView All Competitors NRIFF Stock Analysis - Frequently Asked Questions How do I buy shares of Nuvo Pharmaceuticals? Shares of NRIFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:NRIFF) was last updated on 5/23/2024 by MarketBeat.com Staff From Our PartnersThis could mean the end of the U.S dollar…Colonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 Media**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsBill Clinton Backing Biden Replacement???The Freeport SocietyUrgent Nvidia WarningAltimetryTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeNew Options need New Trading StrategiesNetpicksMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvo Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.